Claims

1-19 (cancelled)

20. (new) An implant having low effect on restenosis for inartificial blood vessels, comprising a substrate which is coated at least partly with a coating of titanium nitrid oxide, which coating in turn is at least partly coated with a substance containing albumin, which substance is generated by a contact limited in time of the coating with a solution of albumin, preferably human albumin.

21. (new) The implant according to claim 20, characterized in that it is designed as coronary stent having a coating made of titanium nitrid oxide with a substance containing albumin, the substance is generated by a contact limited in time with a solution of 1 to 30 % in weight of human albumin.

22. (new) The implant according to claim 20, characterized in that it is designed as coronary stent having a coating made of titanium nitrid oxide with a substance containing albumin, the substance is generated by a contact limited in time with a solution of 5 % in weight of human albumin.

23. (new) The implant according to claim 20, characterized in that the substance is made of medical steel, preferably steel 1440.

24. (new) A process for producing an implant with low effect on restenosis, characterized in that a coating made of titanium nitrid oxide is brought on the substrate under vacuum conditions and that subsequently the coated substrate is brought in contact with a solution containing albumin for a limited time interval.

25. (new) A process for producing an implant with low effect on restenosis, characterized in that a coating made of titanium nitrid oxide is brought on the substrate under vacuum conditions and that subsequently, for a limited time interval, the coated substrate is brought in contact with a solution containing albumin.

26. (new) A process according to claim 25, characterized in that the contact with a solution containing albumin is made by spraying.

27. (new) A process according to claim 26, characterized in that the contact with a solution containing albumin is made by immersing the implant into a solution, whereby the solution contains 1 to 30 %, preferably 1 to 15 % in weight of human albumin.

28. (new) A process according to claim 24, characterized in that the coating made of titanium nitrid oxide is generated in a vacuum oven at a temperature of 500 degrees Celsius.

29. (new) A process according to claim 24, characterized in that the contact with the solution containing albumin occurs after a time interval of 1 minute to 5 hours after the generation of the coating of titanium nitrid oxide.

30. (new) A process according to claim 24, characterized in that the contact with the solution containing albumin occurs without interim storage immediately after the generation of the coating of titanium nitrid oxide.

31. (new) A process according to claim 24, characterized in that the contact with the solution containing albumin is maintained for the duration up to one month for the purpose of storage of the implant.